UNSPSC 51263156: Bunitrolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular structure C14H20N2O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, A42VUS2X73 chemically known as 2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)benzonitrile, hydrochloride, but more commonly known as bunitrolol hydrochloride, which bears US NIH Compound Identifier 31641. European Medicines Agency schedules Bunitrolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00900MIG.

Most nations, for tariff and trade purposes, schedule bunitrolol hydrochloride under HS 29269095 and SITC 51484. As of Q4 2014, BUNITROLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)NCC(COC1CCCCC1C#N)O.CL.

UNSPSC 51263156 Bunitrolol hydrochloride is a Commodity code representing pharmaceutical active ingredients and finished-dose medications procured by state and local health agencies. Recent state and local opportunities tagged under this code show minimal direct relevance to the nominal scope; the most recent solicitations involve naloxone procurement and pharmacy benefit program direct-to-manufacturer contracting, neither of which centers on bunitrolol itself. State and local health departments, county community health agencies, and state HHS commissions issue solicitations in this space, though the actual volume and frequency of bunitrolol-specific procurement requests remain unclear from available records. The code appears to capture a narrow pharmaceutical product category that state and local governments acquire through standard competitive bidding processes, typically with requirements for insurance coverage, E-Verify compliance, drug-free workplace certification, and fixed-fee pricing structures.

Geographic activity centers on Florida and Texas based on recent opportunities. Seminole County, Florida released an IFB (IFB60459723LAS) in June 2026 for naloxone and drug deactivation systems with a response deadline of July 26, 2023, requiring 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs, though this RFI targets pharmacy benefit management capability rather than a specific pharmaceutical commodity. Neither opportunity presents a clear, active procurement pipeline for bunitrolol specifically; the code's state and local activity level appears low, and prospective vendors should verify current demand before committing pursuit resources.